Merck & Co hikes 2024 guidance as Keytruda climb continues
The Pharma Letter
by
5h ago
US pharma giant Merck & Co raised and narrowed its forecasts for profit and sales for 2024 in presenting ..read more
Visit website
Investors intrigued by Cidara’s triple-pronged news update
The Pharma Letter
by
10h ago
US biotech Cidara Therapeutics has announced as many as three major news updates in a single day ..read more
Visit website
Bristol Myers posts strong first quarter sales, axes 2,000 jobs
The Pharma Letter
by
10h ago
In its first quarter 2024 results statement, Bristol Myers Squibb beat expectations on revenues, which ..read more
Visit website
Mammoth Bio inks Crispr-based collaboration with Regeneron
The Pharma Letter
by
10h ago
Regeneron Pharmaceuticals has entered a deal with privately held Mammoth Biosciences to research, develop ..read more
Visit website
NICE backs Novartis' new treatment for pediatric glioma
The Pharma Letter
by
10h ago
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published ..read more
Visit website
Endeavor worthy of $132.5 million Series C
The Pharma Letter
by
10h ago
San Diego, USA-based Endeavor BioMedicines has announced the closing of a $132.5 million Series C financing ..read more
Visit website
Senator Sanders investigating high price of Ozempic and Wegovy in the USA
The Pharma Letter
by
12h ago
A key Senate committee has launched an investigation into how Novo Nordisk prices its popular weight-loss ..read more
Visit website
Investors impressed by Sanofi’s estimate-topping results
The Pharma Letter
by
12h ago
Sanofi shares were up by nearly 4% during Thursday’s early afternoon trading in Paris following its ..read more
Visit website
AstraZeneca's Soriot answers pay doubters with first quarter home run
The Pharma Letter
by
12h ago
Shares in Britain’s largest drugmaker, AstraZeneca, have surged to a multi-month high following better-than-expected ..read more
Visit website
UCB off to a good start into 2024
The Pharma Letter
by
12h ago
Belgium’s largest drugmaker UCB today announced an update on its progress at its annual shareholder ..read more
Visit website

Follow The Pharma Letter on FeedSpot

Continue with Google
Continue with Apple
OR